Overview

Improvement of FeNO and FEF25-75 After Inhaled Corticosteroid Treatment of Asthma

Status:
Completed

Trial end date:
2010-07-01

Target enrollment:
0

Participant gender:
All

Summary

Abnormal lung function and high exhaled nitric oxide (FeNO) have been reported in asymptomatic patients with asthma. The investigators aimed to assess whether FeNO and FEF25-75 improve concurrently after treatment with inhaled corticosteroid (ICS) in patients with controlled asthma. Geometric mean (GM) FeNO and spirometric values in patients 8 to 16 years of age who maintained asthma control without controller medication were compared with healthy controls and patients with uncontrolled asthma who were also not receiving controller medications. Patients with controlled asthma and high FeNO (> 25 ppb) were randomized to ICS treatment or to remain untreated. Changes in spirometric values and GM FeNO from baseline were evaluated after 6 weeks.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Chungbuk National University

Treatments:

Budesonide
Nitric Oxide

Criteria

Inclusion Criteria:

- sensitized to aeroallergens and previously diagnosed to have asthma based on the
documentation of airway hyperresponsiveness (methacholine PC20 ≤ 8 mg/mL) and/or
reversible airflow obstruction (≥ 12% improvement in FEV1 in response to inhaled beta
2-agonist)

- maintained asthma control without controller medication for 3 months or more

- FeNO > 25 ppb

Exclusion Criteria:

- who had significant pulmonary disease other than asthma or a history of
gastroesophageal reflux